drugset
drugset / Trial / NCT05754450

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II

NCT05754450 ↗

Phase 3 Recruiting 2 enrolled AUG Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).

Timeline

Start
2023-04-10
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AVTX-803 Unknown 1700 mg/kg —

Indications

leukocyte adhesion deficiency